# Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

> **NCT04080531** · PHASE4 · COMPLETED · sponsor: **Emory University** · enrollment: 165 (actual)

## Conditions studied

- Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** Pneumococcal 13-valent Conjugate Vaccine
- **BIOLOGICAL:** Trivalent Influenza Vaccine

## Key facts

- **NCT ID:** NCT04080531
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-18
- **Primary completion:** 2021-05-11
- **Final completion:** 2022-12-15
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04080531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04080531, "Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04080531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*